Using Advanced Omics to Identify New Treatments for Adults with Relapsed or Refractory Acute Leukemias

What this Trial Is About

Researchers are investigating Acute RecurrentRefractory Leukemias, including Acute Myeloid Leukemia AML, Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma B and T types, and Acute Biphenotypic Leukemia as defined by WHO 2016. The study aims to identify new treatment targets and potential therapies for patients whose disease has returned or not responded after at least one prior therapy. The main focus is on understanding disease mechanisms using combined omics technologies and functional analyses to find molecules that may offer new treatment options. The study involves molecular and genetic testing of patients blood and bone marrow samples using advanced sequencing methods like Next Generation Sequencing, Single Cell RNA sequencing, and quantitative PCR. In vitro drug sensitivity tests will be performed on isolated disease cells to assess responses to a wide range of drugs. Additional analyses will examine the bone marrow microenvironment and cell signaling molecules. Samples are collected during routine clinical care visits. Participants will provide biological samples such as peripheral blood and bone marrow, which will undergo various genetic, molecular, and functional tests. Researchers will monitor the frequency of alternative therapies identified over 12 months. The study includes ongoing evaluation of the disease through routine clinical visits and sample collections. Participants must consent to these tests and understand the studys goals. The research will improve knowledge of leukemia biology and may guide future treatment strategies.

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention